These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29959803)

  • 21. Alemtuzumab and chronic plaque psoriasis.
    Aslam A; Marsland AM; Rog D; Griffiths CE
    Br J Dermatol; 2013 Jul; 169(1):184-6. PubMed ID: 23834118
    [No Abstract]   [Full Text] [Related]  

  • 22. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.
    Papadavid E; Ferra D; Koumaki D; Dalamaga M; Stamou C; Theodoropoulos K; Rigopoulos D
    Dermatology; 2014; 228(2):107-11. PubMed ID: 24504077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.
    Woo WA; Waite A; Rustin MH; McBride SR
    Br J Dermatol; 2014 Apr; 170(4):989-90. PubMed ID: 24298875
    [No Abstract]   [Full Text] [Related]  

  • 24. Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials.
    Yosipovitch G; Soung J; Weiss J; Muscianisi E; Meng X; Gilloteau I; Elewski BE
    Acta Derm Venereol; 2019 Jul; 99(9):820-821. PubMed ID: 31017248
    [No Abstract]   [Full Text] [Related]  

  • 25. A case of generalized pustular psoriasis following Moderna/NIAID COVID-19 vaccination successfully treated with secukinumab.
    Kusano M; Mukaiyama R; Yamamoto T
    An Bras Dermatol; 2024; 99(5):773-775. PubMed ID: 38937220
    [No Abstract]   [Full Text] [Related]  

  • 26. Secukinumab for psoriasis in a patient with familial Mediterranean fever.
    Cannavò SP; Papaianni V; Bartolotta A; Guarneri C
    Dermatol Ther; 2019 Nov; 32(6):e13122. PubMed ID: 31614038
    [No Abstract]   [Full Text] [Related]  

  • 27. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful response of genital psoriasis to ixekizumab: report of six cases.
    García-Legaz Martínez M; Martínez-Doménech Á; Hernández-Bel P; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Sánchez-Carazo JL; Alegre-de Miquel V; Pérez-Ferriols A
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e325-e327. PubMed ID: 30980763
    [No Abstract]   [Full Text] [Related]  

  • 29. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 31. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dramatic early improvement of psoriasis in an 11-year old boy after four doses of secukinumab following an alternative dosing scheme.
    Hoff J; Spora L; Fang Y; Brüggen MC; Möhrenschlager M
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):e399-e400. PubMed ID: 37909322
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ustekinumab for the treatment of HIV psoriasis.
    Paparizos V; Rallis E; Kirsten L; Kyriakis K
    J Dermatolog Treat; 2012 Dec; 23(6):398-9. PubMed ID: 21787206
    [No Abstract]   [Full Text] [Related]  

  • 35. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
    Oiwa T; Honda T; Otsuka A; Kabashima K
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
    [No Abstract]   [Full Text] [Related]  

  • 36. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 39. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the Editor.
    Gooderham M; Elewski BE; Pariser DM; Sofen H; Mendelsohn AM; Rozzo SJ; Li Q
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e350-e352. PubMed ID: 31033068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.